Filip Janku, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares exciting updates being presented at the ASCO Annual Meeting 2021 in the field of developmental therapeutics. Dr Janku’s highlights include first-in-human study data on RBN-2397, an oral PARP7 inhibitor, in patients with advanced solid tumors; findings from a trial of a selective glutaminase-1 inhibitor; and efficacy and safety data of zenocutuzumab in tumors with NRG1 fusions. Dr Janku also highlights the promise of basket studies in precision oncology, notably the MyPathway HER2 basket study (NCT02091141) which will share interesting data on pertuzumab and trastuzumab in HER2-positive advanced solid tumors. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
